Atenolol Once-daily cardioselective beta blockade for angina pectoris

43Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

The physiology, pharmacokinetics and efficacy of atenolol, a cardioselective β-adrenergic blocking agent, were evaluated in 10 patients with stable angina pectoris in a single-blind, dose-ranging study. After a 1-month control placebo period, atenolol was administered once daily at dosages of 25, 50, 100 and 200 mg for 2-week periods. All patients had fewer anginal attacks and consumed fewer nitroglycerin tablets than during the placebo period. Twenty-four-hour ambulatory ECG recordings showed a decrease in mean hourly heart rate throughout the dosing period, with preservation of diurnal variation. Maximal, symptom-limited, treadmill exercise tests performed 3 hours after drug ingestion showed significantly increased exercise time and decreased double products for all doses, but especially with 100-mg and 200-mg doses. Exercise time 24 hours after drug ingestion continued to show a decrease in maximum heart rate and double product, with 100-mg and 200-mg doses again being most effective. Atenolol serum levels correlated with percent reduction in exercise heart rate and increased exercise time. Serum level rose linearly, with an average elimination half-life of about 10 hours after chronic oral dosing. Thus, atenolol was an effective antianginal agent and suppressed resting and exercise-stressed heart rate for 24 hours after ingestion when given in a 100-mg or 200-mg dose once daily.

Cite

CITATION STYLE

APA

Jackson, G., Schwartz, J., Kates, R. E., Winchester, M., & Harrison, D. C. (1980). Atenolol Once-daily cardioselective beta blockade for angina pectoris. Circulation, 61(3), 555–560. https://doi.org/10.1161/01.CIR.61.3.555

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free